Alvogen Set To Gain Majority Of Lotus In $200M Asset Swap
Multinational pharmaceuticals company Alvogen said Thursday that it and Taiwainese specialty pharmaceuticals maker Lotus Pharmaceutical Co. Ltd. have agreed to a pair of transactions through which Alvogen will swap $200 million...To view the full article, register now.
Already a subscriber? Click here to view full article